|Dr. J. Joseph Kim||CEO, Pres & Director||1.03M||1.51M||1969|
|Mr. Peter D. Kies||Chief Financial Officer||538.36k||N/A||1963|
|Dr. Niranjan Y. Sardesai||Chief Operating Officer||575.44k||90.74k||1968|
|Dr. Mark L. Bagarazzi||Chief Medical Officer||576.45k||N/A||1961|
|Dr. Laurent M. Humeau Ph.D.||Sr. VP of R&D||N/A||N/A||N/A|
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers; prostate, breast, lung, and pancreatic cancers; hepatitis C virus; hepatitis B virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, LLC, The Wistar Institute, University of Pennsylvania, GeneOne Life Science Inc., Regeneron Pharmaceuticals, Inc., Genentech, Inc., Plumbline Life Sciences, Inc., the Parker Institute for Cancer Immunotherapy, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, National Institute of Allergy and Infectious Diseases, United States Military HIV Research Program, U.S. Army Medical Research Institute of Infectious Diseases, National Institutes of Health, HIV Vaccines Trial Network, Defense Advanced Research Projects Agency, and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Inovio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 7. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 3; Compensation: 8.